The estimated Net Worth of Carl Goldfischer is at least 33.7 百万$ dollars as of 11 November 2020. Carl Goldfischer owns over 5,000 units of Epizyme Inc stock worth over 7,350$ and over the last 11 years he sold EPZM stock worth over 33,428,558$. In addition, he makes 231,162$ as Independent Director at Epizyme Inc.
Sign up
Carl Goldfischer EPZM stock SEC Form 4 insiders trading
Carl has made over 12 trades of the Epizyme Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of EPZM stock worth 60,350$ on 11 November 2020.
The largest trade he's ever made was buying 555,555 units of Epizyme Inc stock on 12 January 2016 worth over 4,999,995$. On average, Carl trades about 47,708 units every 70 days since 2013. As of 11 November 2020 he still owns at least 5,000 units of Epizyme Inc stock.
You can see the complete history of Carl Goldfischer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Carl Goldfischer biography
Dr. Carl M. Goldfischer M.D. serves as Independent Director of the Company. Dr. Goldfischer has served as an Investment Partner, Managing Director, member of the board of directors and member of the executive committee of Bay City Capital LLC, or Bay City Capital, a life sciences investment firm and a holder of more than 5% of our voting securities, since January 2000. Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer of ImClone Systems Incorporated, a biopharmaceutical company. Since 2004, Dr. Goldfischer has served on the board of directors of EnteroMedics Inc., a publicly traded medical device company. Dr. Goldfischer received a B.A. from Sarah Lawrence College and an M.D. with honors in Scientific Research from Albert Einstein College of Medicine
What is the salary of Carl Goldfischer?
As the Independent Director of Epizyme Inc, the total compensation of Carl Goldfischer at Epizyme Inc is 231,162$. There are 11 executives at Epizyme Inc getting paid more, with Robert Bazemore having the highest compensation of 4,173,620$.
How old is Carl Goldfischer?
Carl Goldfischer is 61, he's been the Independent Director of Epizyme Inc since 2009. There are 4 older and 14 younger executives at Epizyme Inc. The oldest executive at Epizyme Inc is Kenneth Bate, 69, who is the Independent Director.
What's Carl Goldfischer's mailing address?
Carl's mailing address filed with the SEC is OLE MAALOES VEJ 3, C/O GALECTO, INC., COPENHAGEN N G7, G7, DK-2200.
Insiders trading at Epizyme Inc
Over the last 11 years, insiders at Epizyme Inc have traded over 122,255,844$ worth of Epizyme Inc stock and bought 45,285,781 units worth 322,885,823$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of 394,367$. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth 1,704,500$.
What does Epizyme Inc do?
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
What does Epizyme Inc's logo look like?
Complete history of Carl Goldfischer stock trades at Cymabay Therapeutics Inc、Epizyme Inc、Imara Inc、Galecto
Epizyme Inc executives and stock owners
Epizyme Inc executives and other stock owners filed with the SEC include:
-
Robert Bazemore,
President, Chief Executive Officer, Director -
Shefali Agarwal,
Chief Medical Officer -
Paolo Tombesi,
Chief Financial Officer -
Matthew Ros,
Chief Strategy and Business Officer -
Dr. Shefali Agarwal M.D., MPH,
Exec. VP and Chief Medical & Devel. Officer -
Matthew E. Ros,
Advisor -
Dr. Jeffery L. Kutok M.D., Ph.D.,
Chief Scientific Officer -
Pablo Legorreta,
Director -
Grant Bogle,
Independent Director -
Victoria Richon,
Independent Director -
David Mott,
Independent Chairman of the Board -
Carl Goldfischer,
Independent Director -
Kenneth Bate,
Independent Director -
Andrew Allen,
Independent Director -
Kevin Conroy,
Independent Director -
Michael Giordano,
Director -
Grant C. Bogle,
Pres, CEO, Principal Financial Officer & Director -
Alicia Davis,
IR Contact Officer -
Jeffery Kutok,
Chief Scientific Officer -
Erin Boyer,
Chief People & Culture Officer -
Craig West CFA,
VP of Investor Relations -
John F. Weidenbruch,
Sr. VP, Gen. Counsel & Sec. -
Jason Fredette,
VP of Investor Relations -
Dr. Jeffery L. Kutok,
Chief Scientific Officer -
Joseph Beaulieu,
Controller, Treasurer & Principal Accounting Officer -
Dr. Yi Zhang,
Scientific Co-Founder & Member of The Scientific Advisory Board -
Dr. H. Robert Horvitz,
Co-Founder & Chairman of the Scientific Advisory Board -
Robert A Copeland,
EVP and CSO -
Richard F Pops,
Director -
Susan E Graf,
Chief Business Officer -
Peter Tai Ching Ho,
Chief Development Officer -
Pablo G.Rp Management, Llcr...,
-
Beth C Seidenberg,
Director -
Joseph Beaulieu,
See Remarks -
Suzanne Fleming,
SVP -
M James Barrett,
10% owner -
Ryan D Drant,
10% owner -
Xiii Associates, Llckleiner...,
-
Bio Ventures Iv Qp Lp Scopa...,
-
Perkins Caufield & Byers Xi...,
-
Patrick J Kerins,
10% owner -
City Capital Llc Bay City C...,
-
Scott D Sandell,
10% owner -
European Investment Co Llcc...,
-
Robert J Gould,
President and CEO -
Venture Fund I L.P.Astellas...,
-
Stephen Garbacz,
Principal Accounting Officer -
Ventures Llcamgen Inc Amgen,
-
City Capital Llc Bay City C...,
-
Lukegadicke Ansbert Evnin,
-
Harry R Weller,
10% owner -
Ravi Viswanathan,
10% owner -
Krishna Kittu Kolluri,
10% owner -
Peter J Barris,
10% owner -
Forest Baskett,
10% owner -
Enterprise Associates 13 Lp...,
10% owner -
Kazumi Shiosaki,
Director -
Jason P Rhodes,
President, CFO and Treasurer -
Enterprise Associates 13 Lp...,
-
City Capital Llc Bay City C...,
-
Eric Hedrick,
Chief Medical Officer -
Partners 13, Limited Partne...,
-
Bio Ventures Iv Qp Lp Scopa...,
-
Victoria Vakiener,
Chief Commercial Officer -
Jerald Korn,
Chief Operating Officer -
Carol Stuckley,
Director -
Roy A Beveridge,,
Director -
Pablo G.Rp Management, Llcr...,